Clouded Future for Merck's Blood Thinning Drug Vorapaxar

by Dr. Trupti Shirole on  March 25, 2012 at 6:18 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Merck & Co.'s experimental anti-platelet drug vorapaxar reduces the risk of heart attacks but increases the risk of significant bleeding.

The latest studies have raised questions whether the company will seek approval for the drug from the U.S. Food and Drug Administration.
 Clouded Future for Merck's Blood Thinning Drug Vorapaxar
Clouded Future for Merck's Blood Thinning Drug Vorapaxar

From January 2011 a safety committee overseeing the 26,449-patient study had questioned its efficacy as they found that the new type of anti-platelet drug was not appropriate for patients who had suffered a stroke, due to bleeding risk.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Blood Group Thalassemia Signature Drug Toxicity Blood in Stools - Symptom Evaluation Bombay Blood Group 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive